Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 5
1996 6
1997 4
1998 1
1999 4
2000 4
2001 3
2002 12
2003 11
2004 12
2005 9
2006 11
2007 12
2008 8
2009 12
2010 12
2011 13
2012 9
2013 19
2014 24
2015 28
2016 32
2017 22
2018 24
2019 24
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

286 results
Results by year
Filters applied: . Clear all
Page 1
Current use of PSMA-PET in prostate cancer management.
Maurer T, Eiber M, Schwaiger M, Gschwend JE. Maurer T, et al. Among authors: Gschwend JE. Nat Rev Urol. 2016 Apr;13(4):226-35. doi: 10.1038/nrurol.2016.26. Epub 2016 Feb 23. Nat Rev Urol. 2016. PMID: 26902337 Review.
Gschwend JE, Miller K. Gschwend JE, et al. Oncol Res Treat. 2017;40 Suppl 2:1. doi: 10.1159/000456163. Epub 2017 Apr 3. Oncol Res Treat. 2017. PMID: 28365710 Free article. German. No abstract available.
The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score.
Miller K, Carles J, Gschwend JE, Van Poppel H, Diels J, Brookman-May SD. Miller K, et al. Among authors: Gschwend JE. Eur Urol. 2018 Jul;74(1):17-23. doi: 10.1016/j.eururo.2017.08.035. Epub 2017 Sep 20. Eur Urol. 2018. PMID: 28939004 Clinical Trial.
[Imaging in urology].
Stief CG, Gschwend JE. Stief CG, et al. Among authors: Gschwend JE. Urologe A. 2015 Jul;54(7):947. doi: 10.1007/s00120-015-3894-0. Urologe A. 2015. PMID: 26091651 German. No abstract available.
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer.
Heck MM, Tauber R, Schwaiger S, Retz M, D'Alessandria C, Maurer T, Gafita A, Wester HJ, Gschwend JE, Weber WA, Schwaiger M, Knorr K, Eiber M. Heck MM, et al. Among authors: Gschwend JE. Eur Urol. 2019 Jun;75(6):920-926. doi: 10.1016/j.eururo.2018.11.016. Epub 2018 Nov 22. Eur Urol. 2019. PMID: 30473431
Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial.
Gschwend JE, Heck MM, Lehmann J, Rübben H, Albers P, Wolff JM, Frohneberg D, de Geeter P, Heidenreich A, Kälble T, Stöckle M, Schnöller T, Stenzl A, Müller M, Truss M, Roth S, Liehr UB, Leißner J, Bregenzer T, Retz M. Gschwend JE, et al. Eur Urol. 2019 Apr;75(4):604-611. doi: 10.1016/j.eururo.2018.09.047. Epub 2018 Oct 15. Eur Urol. 2019. PMID: 30337060 Clinical Trial.
Advances in targeted alpha therapy for prostate cancer.
De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O'Sullivan JM, Oya M, Pacilio M, Parker C, Shore N, Sartor O; Targeted Alpha Therapy Prostate Working Group. De Vincentis G, et al. Among authors: Gschwend JE. Ann Oncol. 2019 Nov 1;30(11):1728-1739. doi: 10.1093/annonc/mdz270. Ann Oncol. 2019. PMID: 31418764 Free PMC article.
[Innovative radionuclide use in urology].
Maurer T, Gschwend JE, Schwaiger M, Eiber M. Maurer T, et al. Among authors: Gschwend JE. Urologe A. 2017 Jan;56(1):1-2. doi: 10.1007/s00120-016-0278-z. Urologe A. 2017. PMID: 27885453 German. No abstract available.
286 results
Jump to page